| Ticker: KDUS | 777 Old Saw Mill River Road | |
| Exchange: NASDAQ-National Market | Tarrytown, New York 10591 | |
| Industry: Service | (914) 345-3344 |
| Type of Shares: | Common Shares | Filing Date: | 5/24/96 | |
| U.S. Shares: | 2,750,000 | Offer Date: | 7/17/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $10.50 - $12.50 | |
| Primary Shares: | 2,750,000 | Offer Price: | $7.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.49 | |
| Offering Amount: | $31,625,000 | Selling: | $0.25 | |
| Expenses: | $675,000 | Reallowance: | $0.10 | |
| Shares Out After: | 11,633,190 |
| Manager | Tier | Phone |
| Hambrecht & Quist Incorporated | Lead Manager | (415) 576-3423 |
| Genesis Merchant Group Securities | Co-manager | (800) 833-6482 |
| Montgomery Securities | Co-manager | 4156272220 |
| Auditor: KPMG Peat Marwick | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $4.42 | $1.63 | $1.00 | Assets: | $30.59 |
| Net Income: | -$1.48 | -$0.04 | -$0.16 | Liabilities: | $2.89 |
| EPS: | -$0.16 | $0.00 | Equity: | $27.69 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the discovery of novel small molecule therapeutics that act on targets in human cell signaling pathways. The company has developed proprietary drug discovery technologies based on genetically engineered yeast cells. Cadus uses these and other proprietary technologies to identify human cell surface receptors and other molecule targets, to elucidate the function of such targets and to identify lead compounds that act on such targets. The company conducts drug discovery programs both independently and with its collaborative partners, Bristol-Myers Squibb Company and Solvay Duphar B.V. Cadus is a leader in the development of proprietary technologies that exploit the similarities between yeast and human genes to elucidate gene function and cell signaling pathways. The company has developed four proprietary drug discovery technologies. Two of these technologies are used to identify small molecules that act as agonists or antagonists to cell surface receptors and other targets in the signal transaction pathway. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.